Acurx Pharmaceuticals (NASDAQ: ACXP) has approved a $10 million Bitcoin purchase to hedge against long-term R&D funding depreciation. The biopharmaceutical company aims to leverage Bitcoin's inflation-resistant properties for treasury diversification. Enfusion (NYSE: ENFN) plans to allocate 10% of its excess cash into Bitcoin and Ethereum, seeking to enhance risk-adjusted returns. Meanwhile, Nature's Miracle (NASDAQ: NMHI) has initiated a $5 million Bitcoin treasury program, marking its entry into cryptocurrency as a reserve asset. Bakkt (NYSE: BKKT) reported a 40% year-over-year increase in its cryptocurrency custody services, highlighting a growing trend among non-crypto companies to rely on compliant custodians for Bitcoin market entry.